HealthQuill Switzerland
Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.
Drugs Health Pharma

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Read More
British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug regulator.
Drugs Health Pharma

AstraZeneca’s experimental blood cancer drug gets US priority review

British-Swedish AstraZeneca’s drug for treatment of a form of blood cancer has been granted a Priority Review in the US by the drug.

Read More
Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed anti-fungal drug in the Asia-Pacific region and China.
Drugs Medical Pharma

Basilea Pharmaceutica to get $1.25m license fee from Pfizer

Switzerland’s Basilea Pharmaceutica Ltd. will receive $1.25 million from its partner Pfizer Inc. after the latter exceeded the sales target for a licensed.

Read More
Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.
Drugs Health Pharma

Roche to pay $42 million to Ascidian to make RNA exon editing drugs

Ascidian Therapeutics, a US-based biotechnology company announced a $42 million research pact with Swiss multinational Roche AG for developing gene editing therapies.

Read More
Cordis, a US-based medical device maker, has acquired Switzerland’s MedAlliance for up to $1.1 billion to expand its product portfolio.
Health Medical Pharma

Cordis acquires medical device maker MedAlliance for $1.1 billion

HQ Team October 2, 2023: Cordis, a US-based medical device maker, has acquired Switzerland’s MedAlliance for up to $1.1 billion to expand its.

Read More
Swiss researchers revealed that the artificial cooling of climate through geo-engineering will not work without decarbonization and involves high risks.
Climate Health Pharma

‘Dimming of sun’ to save Antarctic ice fraught with dangers

HQ Team August 14, 2023: The artificial cooling of climate through geo-engineering will not work without decarbonization and involves high risks, Swiss researchers.

Read More
Any hobby with a personal meaning can ward off loneliness, a joint study found.
Health Medical Pharma

Hobby with a personal meaning can fight loneliness, says study

HQ Team June 27, 2023: Any hobby with a personal meaning can ward off loneliness, a joint study found. “Loneliness are known to.

Read More
Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental trials of two drugs to treat chronic kidney diseases.
Drugs Health Pharma

Novartis to acquire Chinook Therapeutics in a $3.5 billion deal

HQ Team June 13, 2023: Swiss drugmaker, Novartis signed a $3.5 billion deal with Chinook Therapeutics to boost the US-based company’s last-stage experimental.

Read More
Larsen and Toubro, one of the world’s top construction companies, got an order worth up to INR 25 billion ($305 million) to set up two plants in northern India.
Climate Health Pharma

India’s L&T bags hydrocarbon order worth up to $305 million 

HQ Team April 10, 2023: Larsen and Toubro, one of the world’s top construction companies, got an order worth up to INR 25.

Read More
Alzheimer's
Drugs Pharma

Roche’s Alzheimer’s drug fails to meet primary target

Roche, a Swiss drugmaker, announced its Alzheimer's drug did not meet the primary goal of slowing the disease during two clinical trials

Read More